Skip to main content

Table 1 Baseline characteristics of the population before and after propensity score matching

From: Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

  Whole study population Matched population
FOLFIRINOX (n = 371) Gemcitabine/nab-paclitaxel (n = 157) P value SMD FOLFIRINOX (n = 151) Gemcitabine/nab-paclitaxel (n = 151) P value SMD
Age (years) 61 (54–67) 64 (57–71) < 0.001 0.38 62 (57–70) 64 (57–70) 0.39 0.05
Sex, male 229 (61.7) 94 (59.9) 0.69 0.04 84 (55.6) 91 (60.3) 0.42 − 0.09
ECOG-PS    0.15 −0.07    0.90 0.03
 0 64 (17.3) 34 (21.7)    33 (21.9) 32 (21.2)   
 1 305 (82.2) 120 (76.4)    116 (76.8) 116 (76.8)   
 2 2 (0.5) 3 (1.9)    2 (1.3) 3 (2.0)   
Tumor sizea 3.7 (3.0–4.8) 4.0 (2.6–5.3) 0.41 0.09 4.0 (3.0–4.8) 3.9 (2.5–5.0) 0.92 0.02
Tumor locationa    0.07 −0.06    0.63 −0.01
 Head/uncinate 115 (37.5) 33 (28.2)    37 (31.9) 33 (28.9)   
 Body/tail 192 (62.5) 84 (72.4)    79 (68.1) 81 (71.1)   
Previous curative surgery 64 (17.3) 40 (25.5) 0.03 0.19 35 (23.2) 37 (24.5) 0.79 0.03
Number of metastatic sites    0.15 0.09    0.78 −0.07
 1 233 (62.8) 97 (61.8)    88 (58.3) 94 (62.3)   
 2 97 (26.1) 34 (21.7)    37 (24.5) 33 (21.9)   
 3 or more 41 (11.1) 26 (16.6)    26 (17.2) 24 (15.9)   
Metastatic sites
 Liver metastases 234 (63.1) 90 (57.3) 0.20 −0.12 88 (58.3) 87 (57.6) 0.91 −0.01
 Peritoneal seeding 100 (27.0) 57 (36.3) 0.03 0.19 53 (35.1) 53 (35.1) 1 0
 Lung metastases 59 (15.9) 38 (24.2) 0.02 0.19 35 (23.2) 35 (23.2) 1 0
 Distant lymph node 125 (33.7) 51 (32.5) 0.79 −0.03 51 (33.8) 49 (32.5) 0.81 −0.03
 Other (bone, adrenal) 38 (10.2) 22 (14.0) 0.20 0.11 16 (10.6) 20 (13.2) 0.48 0.08
Laboratory findings
 WBC (cells/uL) 6.8 (5.6–8.7) 6.6 (5.1–8.4) 0.22 −0.09 6.8 (5.6–8.4) 6.6 (5.1–8.4) 0.687 −0.05
 Hb (g/dL) 12.5 (11.3–13.7) 12.2 (11.1–13.1) 0.03 −0.19 12 (11–13) 12 (11–13) 0.583 0.09
 PLT (× 103 cells/uL) 233 (185–286) 226 (182–287) 0.49 −0.04 235 (189–287) 224 (180–287) 0.338 −0.09
 Bilirubin (mg/dL) 0.6 (0.4–0.9) 0.6 (0.5–0.8) 0.28 −0.07 0.6 (0.4–1.0) 0.6 (0.5–0.8) 0.873 −0.07
 ALP (IU/L) 82 (68–146) 89 (72–123) 0.45 −0.06 88 (66–130) 89 (72–123) 0.874 −0.01
 Albumin (g/dL) 3.9 (3.6–4.2) 4.0 (3.7–4.2) 0.50 0.02 3.9 (3.6–4.2) 4.0 (3.7–4.2) 0.195 0.09
 CA 19–9 (U/mL) 1010 (121–5710) 938 (115–5320) 0.80 −0.54 676 (58–4560) 937 (115–5740) 0.481 −0.02
  1. FFX folfirinox, GnP gemcitabine plus nab-paclitaxel, SMD standardized mean difference, ECOG-PS Eastern Cooperative Oncology Group performance status, WBC white blood cell count, Hb hemoglobin, PLT platelet count, ALP alkaline phosphatase, CA carbohydrate antigen
  2. aExcluding previous curative resection cases